Vanda Pharmaceuticals reported a 1% increase in total net product sales from HETLIOZ® and Fanapt®, reaching $68.0 million in Q4 2021, and a net income of $7.1 million compared to $8.2 million in Q4 2020.
Total net product sales from HETLIOZ® and Fanapt® were $68.0 million, a 1% increase compared to the fourth quarter of 2020.
HETLIOZ® net product sales were $44.1 million compared to $44.2 million in the fourth quarter of 2020.
Fanapt® net product sales were $24.0 million, a 2% increase compared to the fourth quarter of 2020.
Net income was $7.1 million compared to $8.2 million in the fourth quarter of 2020.
Vanda expects full year 2022 total revenues to be between $240 million and $280 million, HETLIOZ® net product sales between $150 million and $180 million, Fanapt® net product sales between $90 million and $100 million, and year-end 2022 Cash to be greater than $440 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance